Going 0-for-4 on a big PhIII program, Novartis scraps their top asthma prospect and signals big trouble for a little biotech

Novartis this morning reported that their asthma drug fevipiprant flunked two more Phase III studies, crushing their hopes in what had been a star …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nals big trou­ble for a lit­tle biotech